LIVMARLI in the European Union

Livmarli TM logo

LIVMARLI® (maralixibat) oral solution has been approved by the European Commission for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older.


SmPC


Outside of the U.S. and the EU, access to LIVMARLI in certain countries is available through our expanded access program.


LIVMARLI® (maralixibat) oral solution is approved for the treatment of cholestatic pruritus in patients with ALGS one year of age and older in the U.S. and two months of age and older in Europe. All other drugs indications are currently investigational.


Important Safety Information

The most frequently occurring adverse reactions in those who were treated with LIVMARLI in clinical trials was diarrhoea and abdominal pain. None of the adverse reactions were considered serious.